Merck bulks up in haematology, buying Imago for $1.35bn While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest ...

MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (MPNs). The ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.